>> SAA: Thank you, Mr. Chair. Orphan works, what an appropriate name for the stuff of everyday life that we all create? Diaries, business memos and photographs that we never bother to mark with our own names. Most of it… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On April 22nd, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dedalus… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) May 4, 2016 Betty Tong, Ph.D. Senior Licensing and Patenting Manager Technology Advancement Office National Institute of Diabetes and Digestive and Kidney Diseases 12A South… Continue Reading
2016:1 KEI Briefing Note
Transparency of Patent Landscapes
April 25, 2016
At an April 12, 2016 WIPO seminar, Reed F. Beall and Amir Attaran presented a paper, “Patent-based Analysis of the World Health Organization’s 2013 Model List of Essential Medicines,” which includes the following odd comment:
Attached here (in docx format) is the October 15, 2015 version of the draft intellectual property right chapter for the proposed Regional Comprehensive Economic Partnership (RCEP).
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) These are the April 17, 2016 KEI comments on the NIH proposed exclusive license to Ovensa, for patents on 5T4 antibodies for cancer treatment and… Continue Reading
This is a comment on the WIPO- commissioned report on the patent landscape for the WHO essential medicines list, published on April 11th, 2016. The report is titled: Patent-based Analysis of the World Health Organization’s 2013 Model List of Essential Medicines, by Reed F. Beall and Amir Attaran, both at the University of Ottawa, Canada. This is is the third collaboration between WIPO’s Thomas (Tom) Bombelles (Head, Global Health, WIPO) and Attaran on the same topic — the patenting of medicines in developing countries.